CN102573823B - 包含反式去甲舍曲林和血清素受体1a激动剂/拮抗剂的组合物及其用途 - Google Patents

包含反式去甲舍曲林和血清素受体1a激动剂/拮抗剂的组合物及其用途 Download PDF

Info

Publication number
CN102573823B
CN102573823B CN201080019852.5A CN201080019852A CN102573823B CN 102573823 B CN102573823 B CN 102573823B CN 201080019852 A CN201080019852 A CN 201080019852A CN 102573823 B CN102573823 B CN 102573823B
Authority
CN
China
Prior art keywords
disorder
pain
disease
transnorsertraline
tablets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080019852.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN102573823A (zh
Inventor
U·坎贝尔
朱迪思·杜恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Publication of CN102573823A publication Critical patent/CN102573823A/zh
Application granted granted Critical
Publication of CN102573823B publication Critical patent/CN102573823B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201080019852.5A 2009-05-13 2010-05-12 包含反式去甲舍曲林和血清素受体1a激动剂/拮抗剂的组合物及其用途 Expired - Fee Related CN102573823B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17799709P 2009-05-13 2009-05-13
US61/177,997 2009-05-13
PCT/US2010/034473 WO2010132521A1 (en) 2009-05-13 2010-05-12 Compositions comprising transnorsertraline and serotonin receptor 1a agonists/ antagonists and uses thereof

Publications (2)

Publication Number Publication Date
CN102573823A CN102573823A (zh) 2012-07-11
CN102573823B true CN102573823B (zh) 2015-01-07

Family

ID=42306730

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080019852.5A Expired - Fee Related CN102573823B (zh) 2009-05-13 2010-05-12 包含反式去甲舍曲林和血清素受体1a激动剂/拮抗剂的组合物及其用途

Country Status (6)

Country Link
US (1) US20120077818A1 (https=)
EP (1) EP2429514A1 (https=)
JP (2) JP2012526832A (https=)
CN (1) CN102573823B (https=)
CA (1) CA2759180A1 (https=)
WO (1) WO2010132521A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8134029B2 (en) 2002-09-16 2012-03-13 Sunovion Pharmaceuticals Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
EP2455075B1 (en) 2005-07-06 2018-06-20 Sunovion Pharmaceuticals Inc. Process for Preparation of trans 4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine
WO2011064769A1 (en) * 2009-11-24 2011-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and pharmaceutical compositions for the treatment of hot flashes
WO2011069032A2 (en) * 2009-12-04 2011-06-09 Sunovion Pharmaceuticals Inc. Formulations, salts and polymorphs of transnorsertraline and uses thereof
JP6436024B2 (ja) 2015-09-14 2018-12-12 住友電気工業株式会社 炭化珪素エピタキシャル基板の製造方法
US20200405867A1 (en) * 2018-01-19 2020-12-31 Sunovion Pharmaceuticals Inc. Oral dosage forms
WO2019182915A1 (en) * 2018-03-19 2019-09-26 The Board Of Trustees Of The Leland Stanford Junior University Treatment of depression
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
WO2020092496A1 (en) * 2018-10-31 2020-05-07 Sunovion Pharmaceuticals Inc. Methods of treating central nervous system disorders
WO2025049588A1 (en) * 2023-08-29 2025-03-06 The Trustees Of Indiana University Novel treatments for optic neuropathies and glaucoma
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0285008A2 (en) * 1987-03-25 1988-10-05 Bristol-Myers Squibb Company The use of buspirone for preparing a pharmaceutical composition for the treatment of alcohol abuse
WO1997031629A1 (en) * 1996-02-29 1997-09-04 Eli Lilly And Company Treatment of sleep disorders
US5858407A (en) * 1992-02-27 1999-01-12 Alza Corporation Method for administering tandospirone
EP1262197A2 (en) * 2001-05-30 2002-12-04 Pfizer Products Inc. Combination treatment for sleep disorders including sleep apnea
WO2003007956A1 (en) * 2001-07-20 2003-01-30 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
WO2003065970A2 (en) * 2001-02-20 2003-08-14 Royal College Of Surgeons Ie Treatment of fibromyalgia and related fatigue syndromes using pindolol
US20040092605A1 (en) * 2002-09-16 2004-05-13 Sepracor, Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide
WO2007030589A2 (en) * 2005-09-09 2007-03-15 Wyeth Pharmaceutical dosage forms and compositions comprising lecoztan
WO2007143267A2 (en) * 2006-05-31 2007-12-13 Sepracor Inc. Treatment of pain disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine and its formamide
US20080262071A1 (en) * 2004-09-17 2008-10-23 Timothy Dinan Pindolol for the Treating Premenstrual Syndrome and Premenstrual Dysphoric Disorder

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5810518A (ja) * 1981-07-14 1983-01-21 Kowa Yakuhin Kogyo Kk アルコ−ル中毒または鎮静催眠薬中毒治療剤
US4634703A (en) * 1985-10-25 1987-01-06 Bristol-Myers Company Method for alleviation of panic disorders
US4687772A (en) * 1986-10-07 1987-08-18 Bristol-Myers Company Method for improvement of short term memory
US5468749A (en) * 1988-08-30 1995-11-21 Gawin; Frank H. Method for treatment of substance addiction
IL91451A0 (en) * 1988-08-30 1990-04-29 Bristol Myers Co Pharmaceutical compositions comprising azapiron compounds and their use in the treatment of addiction
IL97054A (en) * 1990-02-12 1995-10-31 Bristol Meyers Squibb Co Pharmaceutical preparations containing bospirone for the treatment of coma
JPH03246225A (ja) * 1990-02-20 1991-11-01 Bristol Myers Squibb Co メランコリーうつ病の治療法
JPH04327532A (ja) * 1991-01-31 1992-11-17 Bristol Myers Squibb Co 活動過剰を伴う注意力欠乏疾患の治療に使用する医薬製剤
US5330762A (en) * 1992-02-27 1994-07-19 Alza Corporation Tandospiaine antidepressive therapy
ATE192042T1 (de) * 1995-08-16 2000-05-15 Lilly Co Eli Potenzierung von serotonin-wirkstoffresponz
EP0818198A1 (en) * 1996-07-09 1998-01-14 Lilly S.A. Potentiation of drug response by increasing serotonin availability
US6500827B2 (en) * 1998-05-08 2002-12-31 Pharmacia & Upjohn Company Drug combinations
PT1075264E (pt) * 1998-05-08 2005-01-31 Upjohn Co Novas combinacoes farmacologicas de reboxetina e pindolol
JP2002020291A (ja) * 2000-06-30 2002-01-23 Sumitomo Pharmaceut Co Ltd 認知機能障害の治療剤
JP2003335678A (ja) * 2002-05-17 2003-11-25 Sumitomo Pharmaceut Co Ltd 神経因性疼痛治療薬
AU2005283829A1 (en) * 2004-09-17 2006-03-23 Neurocure Ltd Pindolol for the treating premenstrual syndrome and premenstrual dysphoric disorder
EP2455075B1 (en) * 2005-07-06 2018-06-20 Sunovion Pharmaceuticals Inc. Process for Preparation of trans 4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0285008A2 (en) * 1987-03-25 1988-10-05 Bristol-Myers Squibb Company The use of buspirone for preparing a pharmaceutical composition for the treatment of alcohol abuse
US5858407A (en) * 1992-02-27 1999-01-12 Alza Corporation Method for administering tandospirone
WO1997031629A1 (en) * 1996-02-29 1997-09-04 Eli Lilly And Company Treatment of sleep disorders
WO2003065970A2 (en) * 2001-02-20 2003-08-14 Royal College Of Surgeons Ie Treatment of fibromyalgia and related fatigue syndromes using pindolol
EP1262197A2 (en) * 2001-05-30 2002-12-04 Pfizer Products Inc. Combination treatment for sleep disorders including sleep apnea
WO2003007956A1 (en) * 2001-07-20 2003-01-30 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
US20040092605A1 (en) * 2002-09-16 2004-05-13 Sepracor, Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide
US20080262071A1 (en) * 2004-09-17 2008-10-23 Timothy Dinan Pindolol for the Treating Premenstrual Syndrome and Premenstrual Dysphoric Disorder
WO2007030589A2 (en) * 2005-09-09 2007-03-15 Wyeth Pharmaceutical dosage forms and compositions comprising lecoztan
WO2007143267A2 (en) * 2006-05-31 2007-12-13 Sepracor Inc. Treatment of pain disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine and its formamide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AV965,A SELECTIVE 5-HT 1A SILENT ANTAGONIST AS A CANDIDATE FOR ADJUNCTIVE TREATMENT OF COGNITIVE IMPAIRMENT IN SCHIZOPHRENIA;MCKELVY;《SCHIZOPHRENIA BULLETIN》;20050401;第31卷(第2期);305 *

Also Published As

Publication number Publication date
JP2015180673A (ja) 2015-10-15
EP2429514A1 (en) 2012-03-21
CA2759180A1 (en) 2010-11-18
CN102573823A (zh) 2012-07-11
US20120077818A1 (en) 2012-03-29
JP2012526832A (ja) 2012-11-01
WO2010132521A1 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
CN102573823B (zh) 包含反式去甲舍曲林和血清素受体1a激动剂/拮抗剂的组合物及其用途
ES2261234T5 (es) Metabolitos de bupropion y metodos de sintesis y uso.
US20170049777A1 (en) Compositions, methods and uses for the treatment of diabetic neuropathies
KR20160111013A (ko) 신경질환의 치료를 위한 바클로펜, 아캄프로세이트 및 중쇄 트리-글리세리드의 조합
AU2015249065B2 (en) Formulations, salts and polymorphs of transnorsertraline and uses thereof
JP5941258B2 (ja) 他の薬剤と組合せた（ｒ，ｒ）−ホルモテロール
US20080261984A1 (en) Use of S,S-Reboxetine in the Treatment of Pain
US10799499B2 (en) Combinatorial therapies of neurological disorders
JP6084931B2 (ja) ストレス又は急性聴力損失に関連する耳鳴の治療又は予防のためのネラメキサン
CN107206011B (zh) 包括雷洛昔芬以及维生素d或其衍生物的复合胶囊
JP2008502698A (ja) アルブテロール、及びカルシウム活性化カリウムチャネルオープナーの使用方法。
US20080058345A1 (en) Combination Therapy with Mecamylamine for the Treatment of Mood Disorders
US20050228052A1 (en) Methods of treating, preventing and managing a sleep disorder using (S)-didesmethylsibutramine
US20230321010A1 (en) Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms
KR20220110259A (ko) 통증 질환에 사용하기 위한 미르타자핀 및 티자니딘 배합물
JP2020518562A (ja) アルツハイマー病のイダロピルジン系組合せ療法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150107

Termination date: 20190512